PE20091778A1 - Composiciones de alta densidad que contienen posaconazol y formulaciones que lo comprenden - Google Patents

Composiciones de alta densidad que contienen posaconazol y formulaciones que lo comprenden

Info

Publication number
PE20091778A1
PE20091778A1 PE2009000520A PE2009000520A PE20091778A1 PE 20091778 A1 PE20091778 A1 PE 20091778A1 PE 2009000520 A PE2009000520 A PE 2009000520A PE 2009000520 A PE2009000520 A PE 2009000520A PE 20091778 A1 PE20091778 A1 PE 20091778A1
Authority
PE
Peru
Prior art keywords
posaconazole
hpmc
formulations
high density
compositions containing
Prior art date
Application number
PE2009000520A
Other languages
English (en)
Inventor
Larry Yun Fang
David Harris
Gopal Krishna
Allen E Moton Jr
Russel C Prestipino
Marc Steinman
Jiangsheng Wan
Hetty Anne Waskin
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41199703&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091778(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20091778A1 publication Critical patent/PE20091778A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA DE ADMINISTRACION ORAL QUE COMPRENDE POSACONAZOL DISUELTO O MOLECULARMENTE DISPERSO EN UN POLIMERO DERIVADO DE HIDROXIPROPILMETILCELULOSA TAL COMO POLIMERO ACETATO SUCCINATO DE HIDROXIPROPILMETILCELULOSA (HPMC-AS). TAMBIEN ESTA REFERIDA A UN PROCESO DE PREPARACION QUE COMPRENDE: a) COMBINAR EN SECO HPMC-AS Y POSACONAZOL EN UNA PROPORCION DE 1:1 A 4:1, b) CALENTAR LA MEZCLA PREPARADA HASTA UNA TEMPERATURA INFERIOR A LA TEMPERATURA DE TRANSICION VITREA DEL HPMC-AS Y SUPERIOR A LA TEMPERATURA DE FUSION DE LA MEZCLA CON LO CUAL SE FORMA UN FUNDIDO, Y C) ENFRIAR EL FUNDIDO CON LO CUAL SE PROPORCIONA UNA COMPOSICION SOLIDA QUE COMPRENDE POSACONAZOL DISUELTO O MOLECULARMENTE DISPERSO EN HPMC-AS
PE2009000520A 2008-04-15 2009-04-15 Composiciones de alta densidad que contienen posaconazol y formulaciones que lo comprenden PE20091778A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4517708P 2008-04-15 2008-04-15
US16648709P 2009-04-03 2009-04-03

Publications (1)

Publication Number Publication Date
PE20091778A1 true PE20091778A1 (es) 2009-11-13

Family

ID=41199703

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000520A PE20091778A1 (es) 2008-04-15 2009-04-15 Composiciones de alta densidad que contienen posaconazol y formulaciones que lo comprenden

Country Status (19)

Country Link
US (2) US20110123627A1 (es)
EP (1) EP2285351A2 (es)
JP (3) JP2011516612A (es)
KR (1) KR20110004852A (es)
CN (2) CN102065842A (es)
AR (1) AR072858A1 (es)
AU (1) AU2009236289B2 (es)
BR (1) BRPI0910627A2 (es)
CA (1) CA2720849A1 (es)
CL (1) CL2009000902A1 (es)
CO (1) CO6311066A2 (es)
MX (1) MX2010011295A (es)
NZ (1) NZ588460A (es)
PE (1) PE20091778A1 (es)
PH (1) PH12015500492A1 (es)
SG (1) SG10201403986UA (es)
TW (1) TWI388324B (es)
WO (1) WO2009129300A2 (es)
ZA (1) ZA201007370B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009129301A2 (en) * 2008-04-15 2009-10-22 Schering Corporation Oral pharmaceutical compositions in a molecular solid dispersion
ES2706880T3 (es) * 2010-02-22 2019-04-01 Daiichi Sankyo Co Ltd Preparación sólida de liberación sostenida para uso oral
IN2014DE01467A (es) * 2013-06-03 2015-07-24 Shinetsu Chemical Co
EP2837391B1 (en) 2013-08-12 2017-05-10 Shin-Etsu Chemical Co., Ltd. Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate
CN104510707A (zh) * 2013-09-26 2015-04-15 博瑞生物医药技术(苏州)有限公司 一种泊沙康唑固体分散体及其制备方法
CN104546667A (zh) * 2013-10-22 2015-04-29 博瑞生物医药技术(苏州)有限公司 含泊沙康唑的固体分散体及其制备方法
CN104721827A (zh) * 2013-12-18 2015-06-24 博瑞生物医药技术(苏州)有限公司 一种难溶性抗真菌药物固体分散体及其制备方法
AU2015214502B2 (en) 2014-02-05 2019-06-06 Merck Sharp & Dohme Llc Tablet formulation for CGRP-active compounds
CN110179801B (zh) * 2014-04-11 2021-08-06 上海宣泰医药科技股份有限公司 泊沙康唑药物组合物及其制备方法和药物制剂
ES2759801T3 (es) * 2015-08-08 2020-05-12 Tiefenbacher Alfred E Gmbh & Co Kg Formulación gastro-resistente que contiene posaconazol
EP3210599A1 (en) 2016-02-26 2017-08-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Gastro-resistant formulation containing posaconazole and a polymeric precipitation inhibitor
WO2017032908A1 (en) 2016-07-08 2017-03-02 Synthon B.V. Pharmaceutical composition comprising amorphous posaconazole
CN106265526A (zh) * 2016-09-22 2017-01-04 山东大学 一种抗真菌药物泊沙康唑的固体分散体及制备方法与应用
TR201620462A2 (tr) 2016-12-31 2018-07-23 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ
US20180282527A1 (en) 2017-03-30 2018-10-04 Shin-Etsu Chemical Co., Ltd. Injection molding composition containing hypromellose acetate succinate and method for producing same
US10702520B1 (en) 2019-01-29 2020-07-07 Slayback Pharma Llc Pharmaceutical compositions of posaconazole
EP4196096A1 (en) 2020-08-13 2023-06-21 Alfred E. Tiefenbacher (GmbH & Co. KG) Gastro-resistant high-strength formulation containing posaconazole
CN112697937A (zh) * 2020-12-18 2021-04-23 卓和药业集团有限公司 泊沙康唑肠溶片溶出度的分析方法
WO2023012378A1 (en) 2021-11-25 2023-02-09 Alfred E. Tiefenbacher (Gmbh Und Co. Kg) Granules containing posaconazole
EP4091604B1 (en) 2021-11-25 2024-04-03 Alfred E. Tiefenbacher (GmbH & Co. KG) Granules containing posaconazole
CN114184721A (zh) * 2021-12-14 2022-03-15 江苏恒盛药业有限公司 泊沙康唑残留溶剂的检测方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144346A (en) * 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4978672A (en) * 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
GB8908250D0 (en) * 1989-04-12 1989-05-24 Fisons Plc Formulations
US5278175A (en) * 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
US5661151A (en) * 1993-12-21 1997-08-26 Schering Corporation Tetrahydrofuran antifungals
US5703079A (en) * 1993-12-21 1997-12-30 Schering Corporation Tetrahydrofuran antifungals
NZ270418A (en) * 1994-02-07 1997-09-22 Eisai Co Ltd Polycyclic triazole & imidazole derivatives, antifungal compositions
GB9602080D0 (en) * 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds
CA2240161C (en) * 1996-05-20 2005-05-24 Janssen Pharmaceutica N.V. Antifungal compositions with improved bioavailability
US5834472A (en) * 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US5972381A (en) * 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
US5846971A (en) * 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
US6713481B1 (en) * 1997-10-17 2004-03-30 David R. Andrews Crystalline antifungal polymorph
WO2001047492A1 (en) * 1999-12-23 2001-07-05 F H Faulding & Co Limited Improved pharmaceutical compositions for poorly soluble drugs
AR028253A1 (es) * 2000-03-16 2003-04-30 Pfizer Prod Inc Inhibidores de la glucogeno fosforilasa
KR100607742B1 (ko) * 2001-04-03 2006-08-01 쉐링 코포레이션 안정한 액상 현탁제, 및 이를 함유하는, 생체 이용율이 증진된 항진균성 조성물
JPWO2003077827A1 (ja) * 2002-03-19 2005-07-14 日本新薬株式会社 医薬固体分散体の製造方法
US20050043251A1 (en) * 2003-08-20 2005-02-24 Fairfield Clinical Trials, Llc Method of treatment of otitis externa
US20060160823A1 (en) * 2004-05-28 2006-07-20 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmaceutical compositions of Posaconazole
WO2006034080A2 (en) * 2004-09-17 2006-03-30 Nektar Therapeutics Formulation comprising itraconazole
US20060275230A1 (en) * 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
CN101299993A (zh) * 2005-11-04 2008-11-05 伊士曼化工公司 用于给药难溶的药学活性剂的羧烷基纤维素酯
SG170047A1 (en) * 2006-05-30 2011-04-29 Elan Pharma Int Ltd Nanoparticulate posaconazole formulations
CN101702878B (zh) * 2007-05-11 2012-11-28 弗·哈夫曼-拉罗切有限公司 可溶性差的药物的药物组合物
WO2009129301A2 (en) * 2008-04-15 2009-10-22 Schering Corporation Oral pharmaceutical compositions in a molecular solid dispersion

Also Published As

Publication number Publication date
US20150150990A1 (en) 2015-06-04
WO2009129300A3 (en) 2010-02-11
MX2010011295A (es) 2010-11-12
CL2009000902A1 (es) 2010-07-23
BRPI0910627A2 (pt) 2015-09-22
CO6311066A2 (es) 2011-08-22
JP2014139230A (ja) 2014-07-31
SG10201403986UA (en) 2014-10-30
TW200946121A (en) 2009-11-16
CN102065842A (zh) 2011-05-18
KR20110004852A (ko) 2011-01-14
WO2009129300A2 (en) 2009-10-22
NZ588460A (en) 2012-07-27
PH12015500492A1 (en) 2017-04-10
CA2720849A1 (en) 2009-10-22
ZA201007370B (en) 2011-06-29
AU2009236289B2 (en) 2014-08-21
JP2011516612A (ja) 2011-05-26
AR072858A1 (es) 2010-09-29
EP2285351A2 (en) 2011-02-23
JP2016074698A (ja) 2016-05-12
CN104983701A (zh) 2015-10-21
US20110123627A1 (en) 2011-05-26
TWI388324B (zh) 2013-03-11
AU2009236289A1 (en) 2009-10-22

Similar Documents

Publication Publication Date Title
PE20091778A1 (es) Composiciones de alta densidad que contienen posaconazol y formulaciones que lo comprenden
AR110986A2 (es) Composiciones de ecteinascidina, formulaciones liofilizadas, método de preparación y uso
PE20061449A1 (es) Composiciones farmaceuticas comprendiendo imatinib y un retardador de liberacion
AR073123A1 (es) Composicion farmaceutica que comprende un taxano sustancialmente amorfo para utilizarse en el tratamiento de la enfermedad neoplasica
EA201170527A1 (ru) Фармацевтические композиции, включающие соединения бороновой кислоты
ECSP088239A (es) Composición de liberación de fármaco sostenida
PE20100252A1 (es) Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
RU2009138047A (ru) Стабилизация витамина в12
UA94052C2 (uk) Похідні піридазину
HRP20211423T1 (hr) Formulacije enzalutamida
AR075028A1 (es) Composicion farmaceutica solida que comprende amlodipina y losartan
MY150757A (en) Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins
TW200744677A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
SG10201407538WA (en) Intravenous formulations of neurokinin-1 antagonists
EA201290734A1 (ru) Рифаксимин в форме порошка, способ его получения и композиции контролируемого высвобождения, содержащие указанный рифаксимин, полезные для достижения длительного эффекта
TR200806298A2 (tr) Farmasötik formülasyon
AR063983A1 (es) Formulacion de liberacion controlada de agonistas y antagonistas de piperazina -piperidina del receptor 5-ht1a que tienen una disolucion intestinal mejorada
JP2016513128A5 (es)
AR084067A1 (es) Composiciones farmaceuticas
JP2017061576A (ja) 固形組成物
PE20151024A1 (es) Composicion farmaceutica novedosa
EA201490363A1 (ru) Новые составы на основе (триметоксифениламино)пиримидинилов
JP2016535746A5 (es)
EP2497464A3 (en) Pharmaceutical composition of imatinibe methanesulphonate and a process for its manufacture
PE20130782A1 (es) Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo

Legal Events

Date Code Title Description
FG Grant, registration